# Remiges Ventures

> Remiges Ventures is a VC fund in Cambridge backing Biotechnology and Medical. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 24
- Last investment: Apr 2026
- Lead investor: 63%
- Fund size: $95M
- Last fund: Jun 2019
- Last updated: Aug 2026
- Website: http://www.remigesventures.com

Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.

## Contacts

5 contacts available for Remiges Ventures. Shizune tracks 2 team members at Remiges Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/remiges-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.6M–$10M |
| Series A | $6.6M–$25M |
| Series B | $8.2M–$41M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 50% |
| Medical | 6 | 25% |
| Health Care | 5 | 21% |
| Therapeutics | 5 | 21% |
| Life Science | 3 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 42% |
| Series B | 6 | 25% |
| Seed | 3 | 13% |
| Series C | 2 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 29% |
| Japan | 2 | 8% |
| Canada | 1 | 4% |
| France | 1 | 4% |
| Israel | 1 | 4% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Taro Inaba | Founder and Managing Partner | 4 | https://shizune.co/investors/profile/taro-inaba |
| Takahide Koda | Partner | 0 | https://shizune.co/investors/profile/takahide-koda |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Restore Vision | Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $8.2M | Series B | Apr 15, 2026 |  |
| Kupando | Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $11.5M | Series A | Mar 18, 2026 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M | Series C | Apr 16, 2025 |  |
| KisoJi Biotechnology | KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. | $40.6M | Series B | Dec 02, 2024 |  |
| Immunis | Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $25M | Series A | Jul 01, 2024 |  |
| Cyrano Therapeutics | Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significantimprovement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program.Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA. | $9M | Series B | Jan 16, 2024 |  |
| Restore Vision | Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $4.2M | Series A | Dec 15, 2023 |  |
| Restore Vision | Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $9.1M | Series A | Jun 05, 2023 |  |
| Kupando | Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $12.5M | Series A | Sep 26, 2022 |  |
| Immunis | Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $10M | Series A | Aug 03, 2022 |  |

10 of 24 investments shown.

## Co-investors
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 4 deals together
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 4 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 3 deals together
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund, 3 deals together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 3 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)
- [Health Care Investors in Japan](https://shizune.co/investors/health-care-investors-japan)
- [Health Care VC Funds in Japan](https://shizune.co/investors/health-care-vc-funds-japan)
- [Life Science VC Funds in Israel](https://shizune.co/investors/life-science-vc-funds-israel)

## FAQ

### What does Remiges Ventures invest in?

Remiges Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Remiges Ventures's check size?

Remiges Ventures typically joins rounds of $2.6M–$10M at Seed, $6.6M–$25M at Series A and $8.2M–$41M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Remiges Ventures participates in.

### How do I contact Remiges Ventures?

Public channels for Remiges Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Remiges Ventures?

The team at Remiges Ventures includes Taro Inaba (Founder and Managing Partner) and Takahide Koda (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co